Report cover image

Global Ceftriaxone Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20359565

Description

Summary

According to APO Research, the global Ceftriaxone market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Ceftriaxone market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Ceftriaxone market include Qilu Pharmaceutical, Novartis, Baxter International, Orchid Pharma, Nectar Lifesciences, Lupin Pharmaceuticals, Hikma Pharmaceuticals, Aurobindo Pharma and ACS DOBFAR, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ceftriaxone, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ceftriaxone, also provides the sales of main regions and countries. Of the upcoming market potential for Ceftriaxone, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ceftriaxone sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ceftriaxone market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Ceftriaxone sales, projected growth trends, production technology, application and end-user industry.

Ceftriaxone Segment by Company

Qilu Pharmaceutical
Novartis
Baxter International
Orchid Pharma
Nectar Lifesciences
Lupin Pharmaceuticals
Hikma Pharmaceuticals
Aurobindo Pharma
ACS DOBFAR
Ceftriaxone Segment by Type

Intravenous Injection
Intramuscular Injection
Ceftriaxone Segment by Application

Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Ceftriaxone Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Ceftriaxone status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Ceftriaxone market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ceftriaxone significant trends, drivers, influence factors in global and regions.
6. To analyze Ceftriaxone competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ceftriaxone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ceftriaxone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ceftriaxone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ceftriaxone market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ceftriaxone industry.
Chapter 3: Detailed analysis of Ceftriaxone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Ceftriaxone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Ceftriaxone in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Ceftriaxone Sales Value (2020-2031)
1.2.2 Global Ceftriaxone Sales Volume (2020-2031)
1.2.3 Global Ceftriaxone Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Ceftriaxone Market Dynamics
2.1 Ceftriaxone Industry Trends
2.2 Ceftriaxone Industry Drivers
2.3 Ceftriaxone Industry Opportunities and Challenges
2.4 Ceftriaxone Industry Restraints
3 Ceftriaxone Market by Company
3.1 Global Ceftriaxone Company Revenue Ranking in 2024
3.2 Global Ceftriaxone Revenue by Company (2020-2025)
3.3 Global Ceftriaxone Sales Volume by Company (2020-2025)
3.4 Global Ceftriaxone Average Price by Company (2020-2025)
3.5 Global Ceftriaxone Company Ranking (2023-2025)
3.6 Global Ceftriaxone Company Manufacturing Base and Headquarters
3.7 Global Ceftriaxone Company Product Type and Application
3.8 Global Ceftriaxone Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Ceftriaxone Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Ceftriaxone Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Ceftriaxone Market by Type
4.1 Ceftriaxone Type Introduction
4.1.1 Intravenous Injection
4.1.2 Intramuscular Injection
4.2 Global Ceftriaxone Sales Volume by Type
4.2.1 Global Ceftriaxone Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ceftriaxone Sales Volume by Type (2020-2031)
4.2.3 Global Ceftriaxone Sales Volume Share by Type (2020-2031)
4.3 Global Ceftriaxone Sales Value by Type
4.3.1 Global Ceftriaxone Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Ceftriaxone Sales Value by Type (2020-2031)
4.3.3 Global Ceftriaxone Sales Value Share by Type (2020-2031)
5 Ceftriaxone Market by Application
5.1 Ceftriaxone Application Introduction
5.1.1 Retail Pharmacies
5.1.2 Online Pharmacies
5.1.3 Hospital Pharmacies
5.2 Global Ceftriaxone Sales Volume by Application
5.2.1 Global Ceftriaxone Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ceftriaxone Sales Volume by Application (2020-2031)
5.2.3 Global Ceftriaxone Sales Volume Share by Application (2020-2031)
5.3 Global Ceftriaxone Sales Value by Application
5.3.1 Global Ceftriaxone Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Ceftriaxone Sales Value by Application (2020-2031)
5.3.3 Global Ceftriaxone Sales Value Share by Application (2020-2031)
6 Ceftriaxone Regional Sales and Value Analysis
6.1 Global Ceftriaxone Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Ceftriaxone Sales by Region (2020-2031)
6.2.1 Global Ceftriaxone Sales by Region: 2020-2025
6.2.2 Global Ceftriaxone Sales by Region (2026-2031)
6.3 Global Ceftriaxone Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Ceftriaxone Sales Value by Region (2020-2031)
6.4.1 Global Ceftriaxone Sales Value by Region: 2020-2025
6.4.2 Global Ceftriaxone Sales Value by Region (2026-2031)
6.5 Global Ceftriaxone Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Ceftriaxone Sales Value (2020-2031)
6.6.2 North America Ceftriaxone Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Ceftriaxone Sales Value (2020-2031)
6.7.2 Europe Ceftriaxone Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Ceftriaxone Sales Value (2020-2031)
6.8.2 Asia-Pacific Ceftriaxone Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Ceftriaxone Sales Value (2020-2031)
6.9.2 South America Ceftriaxone Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Ceftriaxone Sales Value (2020-2031)
6.10.2 Middle East & Africa Ceftriaxone Sales Value Share by Country, 2024 VS 2031
7 Ceftriaxone Country-level Sales and Value Analysis
7.1 Global Ceftriaxone Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Ceftriaxone Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Ceftriaxone Sales by Country (2020-2031)
7.3.1 Global Ceftriaxone Sales by Country (2020-2025)
7.3.2 Global Ceftriaxone Sales by Country (2026-2031)
7.4 Global Ceftriaxone Sales Value by Country (2020-2031)
7.4.1 Global Ceftriaxone Sales Value by Country (2020-2025)
7.4.2 Global Ceftriaxone Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Ceftriaxone Sales Value Growth Rate (2020-2031)
7.5.2 USA Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Ceftriaxone Sales Value Growth Rate (2020-2031)
7.6.2 Canada Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Ceftriaxone Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Ceftriaxone Sales Value Growth Rate (2020-2031)
7.8.2 Germany Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Ceftriaxone Sales Value Growth Rate (2020-2031)
7.9.2 France Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.9.3 France Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Ceftriaxone Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Ceftriaxone Sales Value Growth Rate (2020-2031)
7.11.2 Italy Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Ceftriaxone Sales Value Growth Rate (2020-2031)
7.12.2 Spain Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Ceftriaxone Sales Value Growth Rate (2020-2031)
7.13.2 Russia Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Ceftriaxone Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Ceftriaxone Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Ceftriaxone Sales Value Growth Rate (2020-2031)
7.16.2 China Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.16.3 China Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Ceftriaxone Sales Value Growth Rate (2020-2031)
7.17.2 Japan Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Ceftriaxone Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Ceftriaxone Sales Value Growth Rate (2020-2031)
7.19.2 India Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.19.3 India Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Ceftriaxone Sales Value Growth Rate (2020-2031)
7.20.2 Australia Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Ceftriaxone Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Ceftriaxone Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Ceftriaxone Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Ceftriaxone Sales Value Growth Rate (2020-2031)
7.24.2 Chile Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Ceftriaxone Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Ceftriaxone Sales Value Growth Rate (2020-2031)
7.26.2 Peru Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Ceftriaxone Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Ceftriaxone Sales Value Growth Rate (2020-2031)
7.28.2 Israel Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Ceftriaxone Sales Value Growth Rate (2020-2031)
7.29.2 UAE Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Ceftriaxone Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Ceftriaxone Sales Value Growth Rate (2020-2031)
7.31.2 Iran Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Ceftriaxone Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Ceftriaxone Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Ceftriaxone Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Ceftriaxone Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Qilu Pharmaceutical
8.1.1 Qilu Pharmaceutical Comapny Information
8.1.2 Qilu Pharmaceutical Business Overview
8.1.3 Qilu Pharmaceutical Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.1.4 Qilu Pharmaceutical Ceftriaxone Product Portfolio
8.1.5 Qilu Pharmaceutical Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.2.4 Novartis Ceftriaxone Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Baxter International
8.3.1 Baxter International Comapny Information
8.3.2 Baxter International Business Overview
8.3.3 Baxter International Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.3.4 Baxter International Ceftriaxone Product Portfolio
8.3.5 Baxter International Recent Developments
8.4 Orchid Pharma
8.4.1 Orchid Pharma Comapny Information
8.4.2 Orchid Pharma Business Overview
8.4.3 Orchid Pharma Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.4.4 Orchid Pharma Ceftriaxone Product Portfolio
8.4.5 Orchid Pharma Recent Developments
8.5 Nectar Lifesciences
8.5.1 Nectar Lifesciences Comapny Information
8.5.2 Nectar Lifesciences Business Overview
8.5.3 Nectar Lifesciences Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.5.4 Nectar Lifesciences Ceftriaxone Product Portfolio
8.5.5 Nectar Lifesciences Recent Developments
8.6 Lupin Pharmaceuticals
8.6.1 Lupin Pharmaceuticals Comapny Information
8.6.2 Lupin Pharmaceuticals Business Overview
8.6.3 Lupin Pharmaceuticals Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.6.4 Lupin Pharmaceuticals Ceftriaxone Product Portfolio
8.6.5 Lupin Pharmaceuticals Recent Developments
8.7 Hikma Pharmaceuticals
8.7.1 Hikma Pharmaceuticals Comapny Information
8.7.2 Hikma Pharmaceuticals Business Overview
8.7.3 Hikma Pharmaceuticals Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.7.4 Hikma Pharmaceuticals Ceftriaxone Product Portfolio
8.7.5 Hikma Pharmaceuticals Recent Developments
8.8 Aurobindo Pharma
8.8.1 Aurobindo Pharma Comapny Information
8.8.2 Aurobindo Pharma Business Overview
8.8.3 Aurobindo Pharma Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.8.4 Aurobindo Pharma Ceftriaxone Product Portfolio
8.8.5 Aurobindo Pharma Recent Developments
8.9 ACS DOBFAR
8.9.1 ACS DOBFAR Comapny Information
8.9.2 ACS DOBFAR Business Overview
8.9.3 ACS DOBFAR Ceftriaxone Sales, Value and Gross Margin (2020-2025)
8.9.4 ACS DOBFAR Ceftriaxone Product Portfolio
8.9.5 ACS DOBFAR Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Ceftriaxone Value Chain Analysis
9.1.1 Ceftriaxone Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Ceftriaxone Sales Mode & Process
9.2 Ceftriaxone Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Ceftriaxone Distributors
9.2.3 Ceftriaxone Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.